INTRAVESICAL BOTULINUM TOXIN A ADMINISTRATION PRODUCES ANALGESIA AGAINST ACETIC ACID INDUCED BLADDER PAIN RESPONSES IN RATS

2004 ◽  
Vol 172 (4 Part 1) ◽  
pp. 1529-1532 ◽  
Author(s):  
YAO-CHI CHUANG ◽  
NAOKI YOSHIMURA ◽  
CHAO-CHENG HUANG ◽  
PO-HUI CHIANG ◽  
MICHAEL B. CHANCELLOR
Keyword(s):  
Acetic Acid ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Bladder Pain ◽  
Pain Responses

358: Intravesical Botulinum Toxin a Administration Produces Analgesia Against Acetic Acid Induced Bladder Pain Responses in Rats

2004 ◽  
Vol 171 (4S) ◽  
pp. 94-94
Author(s):  
Yao-Chi Chuang ◽  
Naoki Yoshimura ◽  
Chao-Cheng Huang ◽  
Po-Hui Chiang ◽  
Michael B. Chancellor
Keyword(s):  
Acetic Acid ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Bladder Pain ◽  
Pain Responses

MP29-18 BOTULINUM TOXIN A BLADDER INJECTION IN THE TREATMENT OF BLADDER PAIN SYNDROME/IC: TRYING TO STANDARDIZE THE TECHNIQUE

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Cristina Gutiérrez ◽  
Carlos Errando ◽  
Nicolas Nervo ◽  
Pedro Araño ◽  
Humberto Villavicencio
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Toxin A ◽  
Bladder Pain

scholarly journals Effect of Botulinum Toxin A on Bladder Pain—Molecular Evidence and Animal Studies

Toxins ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 98 ◽  
Author(s):  
Ting-Chun Yeh ◽  
Po-Cheng Chen ◽  
Yann-Rong Su ◽  
Hann-Chorng Kuo
Keyword(s):  
Botulinum Toxin ◽  
Neurotransmitter Release ◽  
Animal Studies ◽  
Visceral Pain ◽  
Neuromuscular Junctions ◽  
Botulinum Toxin A ◽  
Molecular Evidence ◽  
Toxin A ◽  
Bladder Pain ◽  
Bladder Urothelium

Botulinum toxin A (BTX-A) is a powerful neurotoxin with long-lasting activity that blocks muscle contractions. In addition to effects on neuromuscular junctions, BTX-A also plays a role in sensory feedback loops, suggesting the potentiality for pain relief. Although the only approved indications for BTX-A in the bladder are neurogenic detrusor overactivity and refractory overactive bladder, BTX-A injections to treat bladder pain refractory to conventional therapies are also recommended. The mechanism of BTX-A activity in bladder pain is complex, with several hypotheses proposed in recent studies. Here we comprehensively reviewed properties of BTX-A in peripheral afferent and efferent nerves, the inhibition of nociceptive neurotransmitter release, the reduction of stretch-related visceral pain, and its anti-inflammatory effects on the bladder urothelium. Studies have also revealed possible effects of BTX-A in the human brain. However, further basic and clinical studies are warranted to provide solid evidence-based support in using BTX-A to treat bladder pain.

INTRA-TRIGONAL INJECTION OF BOTULINUM TOXIN A IN PATIENTS WITH BLADDER PAIN SYNDROME - RESULTS AT 9-MONTHS FOLLOW-UP

2009 ◽  
Vol 181 (4S) ◽  
pp. 20-20 ◽  
Author(s):  
Rui A Pinto ◽  
André Silva ◽  
Tiago Lopes ◽  
João F Silva ◽  
Carlos M Silva ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Toxin A ◽  
Bladder Pain

scholarly journals Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders—From Bench to Bedside

Toxins ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 166 ◽  
Author(s):  
Yuan-Hong Jiang ◽  
Wan-Ru Yu ◽  
Hann-Chorng Kuo
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Bladder Capacity ◽  
Active Management ◽  
Toxin A ◽  
Bladder Pain ◽  
Detrusor Contractility ◽  
Intravesical Injection ◽  
Bladder Symptoms ◽  
Bladder Disorders

Bladder oversensitivity arises from several different conditions involving the bladder, bladder outlet, systemic or central nervous system diseases. Increase of the bladder sensation results from activation of the sensory receptors in the urothelial cells or suburothelial tissues. Medical treatment targeting the overactive bladder (OAB) or interstitial cystitis (IC) might relieve oversensitive bladder symptoms (frequency, urgency and pain) in a portion of patients, but a certain percentage of patients still need active management. Botulinum toxin A (BoNT-A) has been demonstrated to have anti-inflammatory and antinociceptive effects in bladder sensory disorders and has been shown effective in the reduction of bladder oversensitivity and the increase of functional bladder capacity. For patients with OAB, urgency and urinary incontinence improved, while in patients with IC, bladder pain could be relieved in association with reduction of bladder oversensitivity after BoNT-A intravesical injection. Histological evidence has confirmed the therapeutic mechanism and clinical efficacy of intravesical BoNT-A injection on patients with OAB or IC. Bladder oversensitivity can also be relieved with the instillation of liposome encapsulated BoNT-A or low energy show waves (LESWs), which enable the BoNT-A molecule to penetrate into the urothelium and suburothelial space without affecting the detrusor contractility. Liposome encapsulated BoNT-A or combined LESWs and BoNT-A instillation might be future treatment alternatives for bladder oversensitivity in sensory bladder disorders.

Sign in / Sign up

Export Citation Format

Share Document